

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Susan WIMER-MACKIN

Application No.: *To Be Assigned* (U.S. Nat'l. Stage  
of PCT/US2005/004678) Group Art Unit: *To Be Assigned*

Filed: August 11, 2006

Examiner: *To Be Assigned*For: **Anthrax Antigens and Methods of Use**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, **Mail Stop Amendment**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,  
Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97  
and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 16-57 cited in the attached  
Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are  
not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were  
previously cited by or submitted to the Office in prior Application Serial Nos.:  
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related  
United States Patent Applications may be found in related United States Patent  
Application Nos.:  
Should the Examiner be unable to locate a document, a copy will be provided  
upon request.

IAP11 Rec'd PCT/PTO 11 AUG 2006

- ☒ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98 because this application was filed after June 30, 2003.
- ☐ Documents \_\_\_\_\_ listed on the attached Form PTO-1449 were cited in a foreign search or examination report corresponding to \_\_\_\_\_ application serial no. \_\_\_\_\_ and mailed on \_\_\_\_\_, cited herein as document \_\_\_\_\_.
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. English language publication \_\_\_\_ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) \_\_\_\_\_ for which an English translation is not available.
- ☒ Documents 17-32 are non-English publications. Abstracts for document nos. 17-31 may be found within each publication. An English abstract of non-English document no. 32, SU 11789218 A1 attached to the end of the publication.
- ☐ The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

PATENT

10/589290

Attorney Docket No. LIGO-009/02US

Application No. *To Be Assigned* (U.S.

Nat'l. Stage of PCT/US2005/004678)


Page 3

IAP11 Rec'd PCT/PTO 11 AUG 2006<sup>1</sup>

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Respectfully submitted,  
COOLEY GODWARD LLP

Dated: August 11, 2006

By:   
Bonnie Weiss McLeod  
Reg. No. 43,255

**USPTO Customer No. 58249**

COOLEY GODWARD LLP

ATTN: Patent Group

The Bowen Building

875 15th Street, NW Suite 800

Washington, DC 20005-2221

Phone: (202) 842-7800

Fax: (202) 842-7899

<b>INFORMATION DISCLOSURE CITATION</b>				Attorney Docket No. LIGO-009/02US		Application No. <i>To Be Assigned</i>	
(Use several sheets if necessary)				Applicants: Susan WIMER-MACKIN      PAGE 1 of 3			
PTO Form 1449				Filing Date: August 11, 2006		Group Art Unit: <i>To Be Assigned</i>	
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	2003/0198651	10/23/2003	Klimpel <i>et al.</i>			
	2.	2003/0118591	06/26/2003	Levy			
	3.	4,172,126	10/23/1979	Okonogi <i>et al.</i>			
	4.	4,436,727	03/13/1984	Ribi			
	5.	4,436,728	03/13/1984	Ribi <i>et al.</i>			
	6.	4,912,094	03/27/1990	Myers <i>et al.</i>			
	7.	5,674,908	10/07/1997	Haces <i>et al.</i>			
	8.	5,962,428	10/05/1999	Carrano <i>et al.</i>			
	9.	6,197,755	03/06/2001	Carrano <i>et al.</i>			
	10.	6,329,156	12/11/2001	Cirino <i>et al.</i>			
	11.	6,348,450	02/19/2002	Tang <i>et al.</i>			
	12.	6,387,665	05/14/2002	Farchaus <i>et al.</i>			
	13.	6,592,872	07/15/2003	Klimpel <i>et al.</i>			
	14.	6,602,510	08/05/2003	Fikes <i>et al.</i>			
	15.	6,770,479	08/03/2004	Lee <i>et al.</i>			
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Class	Sub-Class	Translation
	16.	AU 758019	03/13/2003	Australia			
	17.	RU 1566532 C	12/20/1995	Russia			Abstract
	18.	RU 2056861 C1	03/27/1996	Russia			Abstract
	19.	RU 2095409 C1	11/10/1997	Russia			Abstract
	20.	RU 2112544 C1	06/10/1998	Russia			Abstract
	21.	RU 2115433 C1	07/20/1998	Russia			Abstract
	22.	RU 2123532 C1	12/20/1998	Russia			Abstract
	23.	RU 2141340 C1	11/20/1999	Russia			Abstract
	24.	RU 2142009 C1	11/27/1999	Russia			Abstract
	25.	RU 2142010 C1	11/27/1999	Russia			Abstract
	26.	RU 2151798 C1	06/27/2000	Russia			Abstract
	27.	RU 2180917 C1	03/27/2002	Russia			Abstract
	28.	RU 2181294 C2	04/20/2002	Russia			Abstract
	29.	RU 2181296 C2	04/20/2002	Russia			Abstract
	30.	RU 2191599 C1	10/27/2002	Russia			Abstract
	31.	RU 2198921 C2	02/20/2003	Russia			Abstract
Examiner			Date Considered				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  <b>PTO Form 1449</b>				<b>Attorney Docket No.</b> LIGO-009/02US		<b>Application No.</b> <i>To Be Assigned</i>			
				<b>Applicants:</b> Susan WIMER-MACKIN				<b>PAGE 2 of 3</b>	
				<b>Filing Date:</b> August 11, 2006		<b>Group Art Unit:</b> <i>To Be Assigned</i>			
<b>FOREIGN PATENT DOCUMENTS</b>									
		<b>Document No.</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Sub-Class</b>	<b>Translation</b>		
	32.	SU 1789218 A1	01/23/1993	Soviet Union			Derwent abstract attached		
	33.	WO 98/11914 A1	03/26/1998	WIPO					
	34.	WO 00/02522 A2	01/20/2000	WIPO					
	35.	WO 03/048390 A1	06/12/2003	WIPO					
	36.	WO 03/049670 A2	06/19/2003	WIPO					
	37.	WO 2004/004654 A2	01/15/2004	WIPO					
	38.	WO 2005/000884 A1	01/06/2005	WIPO					
	39.	WO 2005/007804 A2	01/27/2005	WIPO					
	40.	WO 2005/048918 A2	06/02/2005	WIPO					
	41.	WO 2005/068493 A1	07/28/2005	WIPO					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>									
	42.	Boyaka <i>et al.</i> , "Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen," <i>J. Immunol.</i> 170:5636-5643 (2003).							
	43.	Chabot <i>et al.</i> , "Anthrax capsule vaccine protects against experimental infection," <i>Vaccine</i> 23:43-47 (2004).							
	44.	Daubenspeck <i>et al.</i> , "Novel Oligosaccharide Side Chains of the Collagen-like Region of BclA, the Major Glycoprotein of the <i>Bacillus anthracis</i> Exosporium," <i>J. Biol. Chem.</i> 279:30945-30953 (2004).							
	45.	Flick-Smith <i>et al.</i> , "Mucosal or Parenteral Administration of Microsphere-Associated <i>Bacillus anthracis</i> Protective Antigen Protects against Anthrax Infection in Mice," <i>Infect. Immunity</i> 70:2022-2028 (2002).							
	46.	Gaur <i>et al.</i> , "Effect of nasal immunization with protective antigen of <i>Bacillus anthracis</i> on protective immune response against anthrax toxin," <i>Vaccine</i> 20:2836-2839 (2002).							
	47.	Ivins <i>et al.</i> , "Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques," <i>Vaccine</i> 16:1141-1148 (1998).							
	48.	Kozel <i>et al.</i> , "mAbs to <i>Bacillus anthracis</i> capsular antigen for immunoprotection in anthrax and detection of antigenemia," <i>Proc. Natl. Acad. Sci. USA</i> 101:5042-5047 (2004).							
	49.	LaForce, "Anthrax," <i>Clin. Infect. Dis.</i> 19:1009-1014 (1994).							
Examiner				Date Considered					
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  <b>PTO Form 1449</b>		<b>Attorney Docket No.</b> LIGO-009/02US	<b>Application No.</b> <i>To Be Assigned</i>	
		<b>Applicants:</b> Susan WIMER-MACKIN		<b>PAGE 3 of 3</b>
		<b>Filing Date:</b> August 11, 2006	<b>Group Art Unit:</b> <i>To Be Assigned</i>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
	50.	Mikszta <i>et al.</i> , "Protective Immunization against Inhalational Anthrax : A Comparison of Minimally Invasive Delivery Platforms," <i>J. Infect. Dis.</i> <b>191</b> :278-288 (2005).		
	51.	Reynolds, "Modulating airway defenses against microbes," <i>Curr. Opin. Pulmonary Med.</i> <b>8</b> : 1 page abstract (2002)		
	52.	Rhie <i>et al.</i> , "A dually active anthrax vaccine that confers protection against both bacilli and toxins," <i>Proc. Natl. Acad. Sci. USA</i> <b>100</b> :10925-10930 (2003).		
	53.	Schneerson <i>et al.</i> , "Poly( $\gamma$ -D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of <i>Bacillus anthracis</i> : A potential addition to the anthrax vaccine," <i>Proc. Natl. Acad. Sci. USA</i> <b>100</b> :8945-8950 (2003).		
	54.	Sigma-Aldrich, "MPL® + TDM Adjuvant System," 2 pages, Sigma-Aldrich (publication date unknown).		
	55.	Sylvestre <i>et al.</i> , "Polymorphism in the Collagen-Like Region of the <i>Bacillus anthracis</i> BclA Protein Leads to Variation in Exosporium Filament Length," <i>J. Bacteriol.</i> <b>185</b> :1555-1563 (2003).		
	56.	Sylvestre <i>et al.</i> , "A collagen-like surface glycoprotein is a structural component of the <i>Bacillus anthracis</i> exosporium,," <i>Mol. Microbiol.</i> <b>45</b> :169-178 (2002).		
	57.	Wimer-Mackin <i>et al.</i> , "An intranasal vaccine targeting both the <i>Bacillus anthracis</i> toxin and bacterium provides protection against aerosol spore challenge in rabbits," <i>Vaccine</i> <b>24</b> :3953-3963 (2006).		
Examiner		Date Considered		
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				